X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
once-weekly dalbavancin (86) 86
humans (63) 63
index medicus (52) 52
pharmacology & pharmacy (49) 49
teicoplanin - analogs & derivatives (47) 47
dalbavancin (40) 40
soft-tissue infections (40) 40
anti-bacterial agents - therapeutic use (39) 39
resistant staphylococcus-aureus (39) 39
anti-bacterial agents - pharmacology (33) 33
complicated skin (31) 31
microbiology (29) 29
skin-structure infections (28) 28
teicoplanin - pharmacology (28) 28
infectious diseases (27) 27
in-vitro activity (25) 25
teicoplanin - therapeutic use (24) 24
anti-bacterial agents - adverse effects (23) 23
gram-positive bacterial infections - drug therapy (23) 23
skin (23) 23
microbial sensitivity tests (22) 22
teicoplanin - adverse effects (22) 22
acute bacterial skin (21) 21
skin diseases, bacterial - drug therapy (19) 19
therapy (18) 18
vancomycin (18) 18
animals (17) 17
anti-bacterial agents - pharmacokinetics (17) 17
antibiotics (17) 17
pharmacokinetics (17) 17
teicoplanin - pharmacokinetics (16) 16
double-blind (15) 15
gram-positive bacterial infections - microbiology (15) 15
dosage and administration (14) 14
glycopeptide (14) 14
in-vitro (14) 14
gram-positive pathogens (13) 13
lipoglycopeptide (13) 13
single-dose oritavancin (13) 13
spectrum (13) 13
female (12) 12
gram-positive bacteria - drug effects (12) 12
internal medicine (12) 12
male (12) 12
research (12) 12
glycopeptides - therapeutic use (11) 11
gram-positive bacteria (11) 11
methicillin-resistant staphylococcus aureus (11) 11
vancomycin - pharmacology (11) 11
anti-bacterial agents - administration & dosage (10) 10
care and treatment (10) 10
drug therapy (10) 10
oritavancin (10) 10
streptococcus - drug effects (10) 10
teicoplanin - administration & dosage (10) 10
treatment outcome (10) 10
antistaphylococcal activity (9) 9
drug resistance, bacterial (9) 9
infections (9) 9
semisynthetic glycopeptide (9) 9
soft tissue infections - drug therapy (9) 9
staphylococcus aureus (9) 9
telavancin (9) 9
united states (9) 9
antibacterial agents (8) 8
clinical trials as topic (8) 8
daptomycin (8) 8
health aspects (8) 8
in-vitro activities (8) 8
linezolid (8) 8
medicine & public health (8) 8
mrsa (8) 8
practice guidelines (8) 8
staphylococcus infections (8) 8
vancomycin resistance (8) 8
aminoglycosides - therapeutic use (7) 7
bacteria (7) 7
bacterial infections - drug therapy (7) 7
drug resistance (7) 7
drug resistance in microorganisms (7) 7
drug resistance, multiple, bacterial (7) 7
glycopeptides - pharmacology (7) 7
half-life (7) 7
infection (7) 7
infectious disease (7) 7
methicillin-resistant staphylococcus aureus - drug effects (7) 7
middle aged (7) 7
staphylococcal infections - drug therapy (7) 7
staphylococcus - drug effects (7) 7
staphylococcus aureus - drug effects (7) 7
staphylococcus-aureus (7) 7
toxicology (7) 7
vancomycin - therapeutic use (7) 7
acute disease (6) 6
adult (6) 6
antimicrobial agents (6) 6
bi 397 (6) 6
biochemical phenomena, metabolism, and nutrition (6) 6
daptomycin - pharmacology (6) 6
glycopeptides - adverse effects (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 5/2010, Volume 70, Issue 7, pp. 859 - 886
Dalbavancin, oritavancin and telavancin are semisynthetic lipoglycopeptides that demonstrate promise for the treatment of patients with infections caused by... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Bacterial-infections, treatment | Oritavancin, general | Research-and- development | Glycoproteins, therapeutic use | Telavancin, general | Antimicrobial-resistance | Dalbavancin, general | Skin-and-soft-tissue-infections, treatment | SOFT-TISSUE INFECTIONS | GLYCOPEPTIDE ANTIBIOTICS | GRAM-POSITIVE BACTERIA | CELL-WALL SYNTHESIS | SKIN-STRUCTURE INFECTIONS | ONCE-WEEKLY DALBAVANCIN | ENTEROCOCCUS-FAECIUM | PHARMACOLOGY & PHARMACY | TOXICOLOGY | RESISTANT STAPHYLOCOCCUS-AUREUS | IN-VITRO ACTIVITY | COMPLICATED SKIN | Humans | Glycopeptides - chemistry | Teicoplanin - therapeutic use | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Drug Interactions | Anti-Bacterial Agents - chemistry | Gram-Positive Bacterial Infections - microbiology | Anti-Bacterial Agents - adverse effects | Molecular Structure | Glycopeptides - pharmacokinetics | Teicoplanin - pharmacokinetics | Teicoplanin - analogs & derivatives | Aminoglycosides - pharmacokinetics | Teicoplanin - chemistry | Aminoglycosides - chemistry | Treatment Outcome | Clinical Trials as Topic | Glycopeptides - adverse effects | Glycopeptides - therapeutic use | Teicoplanin - adverse effects | Animals | Anti-Bacterial Agents - pharmacokinetics | Aminoglycosides - adverse effects | Gram-Positive Bacterial Infections - drug therapy | Drug Resistance, Multiple, Bacterial - drug effects | Aminoglycosides - therapeutic use | Complications and side effects | Gram-positive bacterial infections | Peptides | Dosage and administration | Research | Comparative analysis | Drug therapy | Antibacterial agents | Health aspects
Journal Article
Annals of Pharmacotherapy, ISSN 1060-0280, 11/2019, Volume 53, Issue 11, pp. 1093 - 1101
Background: Although dalbavancin’s (DBV’s) long half-life and one-time dosing strategy confer ideal administration in the ambulatory setting, the optimal role... 
ABSSSI | emergency department | dalbavancin | telehealth | cellulitis | ACUTE BACTERIAL SKIN | THERAPY | ONCE-WEEKLY DALBAVANCIN | PHARMACOLOGY & PHARMACY
Journal Article
Journal Article
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 10/2015, Volume 35, Issue 10, pp. 935 - 948
Health care–associated infections, especially those caused by multidrug‐resistant gram‐positive organisms, such as methicillin‐resistant Staphylococcus aureus... 
oritavancin | infection | gram‐positive | lipoglycopeptide | dalbavancin | resistance | gram-positive | HERSHEY-MEDICAL-CENTER | ONCE-WEEKLY DALBAVANCIN | ECHO DOUBLE-RESONANCE | RESISTANT STAPHYLOCOCCUS-AUREUS | ACUTE BACTERIAL SKIN | SKIN-STRUCTURE INFECTIONS | SURVEILLANCE PROGRAM | ENTEROCOCCUS-FAECIUM | PHARMACOLOGY & PHARMACY | SINGLE-DOSE ORITAVANCIN | IN-VITRO ACTIVITY | Skin Diseases, Bacterial - microbiology | United States | Glycopeptides - administration & dosage | Humans | Half-Life | Skin Diseases, Bacterial - drug therapy | Teicoplanin - therapeutic use | Methicillin-Resistant Staphylococcus aureus | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Drug Interactions | Gram-Positive Bacterial Infections - microbiology | Teicoplanin - pharmacology | Anti-Bacterial Agents - adverse effects | Teicoplanin - analogs & derivatives | Vancomycin Resistance | Glycopeptides - adverse effects | Cross Infection - drug therapy | Glycopeptides - therapeutic use | Randomized Controlled Trials as Topic | Teicoplanin - adverse effects | Teicoplanin - administration & dosage | Animals | Cross Infection - microbiology | Anti-Bacterial Agents - pharmacology | Glycopeptides - pharmacology | Gram-Positive Bacterial Infections - drug therapy | Anti-Bacterial Agents - administration & dosage | Staphylococcus infections | FDA approval
Journal Article
International Journal of Antimicrobial Agents, ISSN 0924-8579, 04/2018, Volume 51, Issue 4, pp. 571 - 577
Dalbavancin is a lipoglycopeptide with a very prolonged half-life enabling treatment with a single intravenous administration that has been approved to treat... 
Gram-positive infection | Skin and soft-tissue infection | Dalbavancin | SOFT-TISSUE INFECTIONS | INFECTIOUS DISEASES | MANAGEMENT | ONCE-WEEKLY DALBAVANCIN | MICROBIOLOGY | RESISTANT STAPHYLOCOCCUS-AUREUS | COMPLICATED SKIN | ACUTE BACTERIAL SKIN | SKIN-STRUCTURE INFECTIONS | PARENTERAL ANTIMICROBIAL THERAPY | PHARMACOLOGY & PHARMACY | CONVENTIONAL THERAPY | CLINICAL-OUTCOMES | Humans | Middle Aged | Soft Tissue Infections - economics | Male | Teicoplanin - therapeutic use | Osteomyelitis - drug therapy | Prosthesis-Related Infections - drug therapy | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Staphylococcal Skin Infections - drug therapy | Prosthesis-Related Infections - economics | Prosthesis-Related Infections - microbiology | Enterococcus - isolation & purification | Female | Anti-Bacterial Agents - adverse effects | Retrospective Studies | Soft Tissue Infections - drug therapy | Teicoplanin - analogs & derivatives | Catheter-Related Infections - economics | Osteomyelitis - economics | Methicillin-Resistant Staphylococcus aureus - drug effects | Catheter-Related Infections - drug therapy | Spain | Teicoplanin - adverse effects | Soft Tissue Infections - microbiology | Osteomyelitis - microbiology | Catheter-Related Infections - microbiology | Cost-Benefit Analysis | Aged | Enterococcus - drug effects | Methicillin-Resistant Staphylococcus aureus - isolation & purification
Journal Article
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 01/2010, Volume 30, Issue 1, pp. 80 - 94
Journal Article
DRUGS, ISSN 0012-6667, 2008, Volume 68, Issue 5, pp. 639 - 648
Dalbavancin is a semisynthetic glycopeptide antibacterial agent that is active against Gram-positive bacteria associated with complicated skin and skin... 
SOFT-TISSUE INFECTIONS | UNITED-STATES | IN-VITRO | ANTISTAPHYLOCOCCAL ACTIVITY | PHARMACOKINETICS | MEDICAL-CENTERS | GLYCOPEPTIDE | ONCE-WEEKLY DALBAVANCIN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | RESISTANT STAPHYLOCOCCUS-AUREUS | COMPLICATED SKIN
Journal Article
Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 06/2014, Volume 41, Issue 6, pp. 437 - 443
Journal Article